Probiodrug Ag

Osi Pharmaceuticals, Inc.

Ingenium Pharmaceuticals Gmbh

André Johannes Niestroj

Ulrich Heiser

Hans-Ulrich Demuth

Torsten Hoffmann

Mirko Buchholz

Michael A Pleiss

Stephan Schilling

Jens-Ulrich Rahfeld

Michael Thormann

Andreas Treml

Michael Almstetter

Robert Sommer

Hans Allgeier

Martin Augustin

Lutz Zeitlmann

Matthias Hoffmann

Anke Mueller

Bernd Gerhartz

Anke Müller

Andreas Marquardt

Ingo Schulz

Joachim Baer

Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: 

Inhibitors of glutaminyl cyclase

Compounds of formula (I), combinations and uses thereof for disease therapy,  

Compounds of general formula (I): are useful as inhibitors of cyclin dependent kinases such as CDK9.

Inhibitors of protein kinases

The present invention relates to novel inhibitors of prolyl endopeptidase of formula 1W&#x2014;KCONH&#x2014;X&#x2014;CON&#x2014;Y&#x2014;CO&#x2014;Z&#x2003;&#x2003;(1)wherein K, W, X, Y and Z are specified in the description. The compounds are useful for the treatment of diseases such as mild cognitive impairment (MCI), Alzheimer's disease, Down Syndrome, Parkinson disease and Chorea Huntington.

Compounds for the treatment of neurological disorders

The present invention relates to compounds of the general formula 1 and pharmaceutically acceptable salts thereof, to the use of the compounds for the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidosis, diabetes mellitus, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus in mammals.

Peptidyl ketones as inhibitors of DPIV

The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/oinfections, colorectal cancer, Zolliger-Ellison syndrome, Familial British Dementia and Familial Danish Dementia.

Use of effectors of glutaminyl and glutamate cyclases

Presented are compounds represented by the following general formulas (I) and (II), for inhibiting cysteine protease legumain for modulating associated disease states in subjects 

Irreversible cysteine protease inhibitors of legumain

Growing community of inventors

Sennewitz, Germany

André Johannes Niestroj